{"url_path":"/sec/bixt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-023538-index.html","accession_number":"0001493152-26-023538","cik":"0001445815","ticker":"BIXT","issuer_name":"BIOXYTRAN, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-023538-index.html","primary_entity_key":"0001445815","primary_entity_name":"BIOXYTRAN, INC"},"word_count":241,"has_tables":true,"body_markdown":"**Item\n6. Exhibits**\n\n \n\n**Exhibit\nNo.**\n \n**Title\nof Document**\n\n \n \n \n\n31.1\n\n*\n[Certification\nof Principal Executive and Financial Officers pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange\nAct of 1934, as amended.](ex31-1.htm)\n\n \n \n \n\n32.1\n**\n[Certification\npursuant to Section 906 of Sarbanes Oxley Act of 2002 (Chief Executive and Financial Officer).](ex32-1.htm)\n\n \n \n \n\n100\n\n*\nThe\nfollowing financial statements from the Quarterly Report on Form 10-Q of BIOXYTRAN, Inc. for the quarter ended March 31, 2026, formatted\nin XBRL: (i) Condensed Balance Sheets (unaudited), (ii) Condensed Statements of Operations (unaudited), (iii) Condensed Statements\nof Cash Flows (unaudited), and (iv) Notes to Condensed Financial Statements (unaudited), tagged as blocks of text.\n\n \n \n \n\n101.INS\n*\nInline\nXBRL Instance Document\n\n \n \n \n\n101.SCH\n*\nInline\nXBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL\n*\nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n \n \n \n\n101.DEF\n*\nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n\n \n \n \n\n101.LAB\n*\nInline\nXBRL Taxonomy Extension Label Linkbase Document\n\n \n \n \n\n101.PRE\n*\nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n \n \n \n\n104\n*\nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled\nas an exhibit hereto.\n\n \n \n\n**\nThese\ncertificates are furnished to, but shall not be deemed to be filed with, the Securities and Exchange Commission.\n\n** **\n\n26\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nIn\naccordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,\nthere unto duly authorized.\n\n \n\n \n**BIOXYTRAN,\nINC.**\n\n \n \n\nDate:\nMay 15, 2026\nBy:\n\n*/s/\nDavid Platt*\n\n \n \nDavid\nPlatt\n\n \n \nChief\nExecutive Officer\n\n \n \n \n\nBy:\n\n*/s/\nOla Soderquist*\n\n \n \nOla Soderquist\n\n \n \nChief\nFinancial Officer\n\n \n\n27"}